2022
DOI: 10.3390/cancers14051232
|View full text |Cite
|
Sign up to set email alerts
|

Matrix Metalloproteinase-1 (MMP1) Upregulation through Promoter Hypomethylation Enhances Tamoxifen Resistance in Breast Cancer

Abstract: Background: Tamoxifen (tam) is widely used to treat estrogen-positive breast cancer. However, cancer recurrence after chemotherapy remains a major obstacle to achieve good patient prognoses. In this study, we aimed to identify genes responsible for epigenetic regulation of tam resistance in breast cancer. Methods: Methylation microarray data were analyzed to screen highly hypomethylated genes in tam resistant (tamR) breast cancer cells. Quantitative RT-PCR, Western blot analysis, and immunohistochemical staini… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
5
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 12 publications
(5 citation statements)
references
References 45 publications
0
5
0
Order By: Relevance
“…In addition, RUNX2-mediated increment of MMP1 levels has been associated with chemoresistance [38]. Regarding drug resistance, MMP1 promoter hypomethylation increases tamoxifen resistance in hormone receptor-positive breast cancer [39]. Therefore, several publications support the role of MMP1 in aggressiveness in different malignancies.…”
Section: Discussionmentioning
confidence: 99%
“…In addition, RUNX2-mediated increment of MMP1 levels has been associated with chemoresistance [38]. Regarding drug resistance, MMP1 promoter hypomethylation increases tamoxifen resistance in hormone receptor-positive breast cancer [39]. Therefore, several publications support the role of MMP1 in aggressiveness in different malignancies.…”
Section: Discussionmentioning
confidence: 99%
“…ascertained the MMP1-dependent effect in hepatocellular carcinoma (HCC) progression via interacting with HuR and the metastasis of colorectal cancer via orchestrating the DDX3/YY1/MMP1/PI3K-AKT axis, respectively ( 26 , 27 ). It’s noteworthy that MMP1 upregulation by promoter hypomethylation has been reported with enhanced tamoxifen resistance in breast cancer ( 28 ). In this study, by conducting multifaceted cellular and molecular analyses, we for the first time identified a specific binding motif in the promoter of MMP1 for the direct transmission of the tumorigenic effect of RUNX2, which would supply novel target candidates for drug development and clinical intervention decision against the proliferation, metastasis (e.g., migration, invasion) and drug resistance of TNBC ( 29 , 30 ).…”
Section: Discussionmentioning
confidence: 99%
“…MMP-1 was also reported to be involved in tamoxifen resistance in breast cancer. Downregulation of MMP1 in tamoxifen-resistant breast cancer cells induced tamoxifen sensitivity in vitro and retarded tumor growth in vivo (98).…”
Section: Pro-tumorigenic Mmpsmentioning
confidence: 99%